KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Real-world data in patients with BRCA mutated breast cancer treated with poly (ADP-ribose) polymerase inhibitors.

Evelyn Lilian Beas-Lozano, Haydeé Cristina Verduzco-Aguirre, Roberto Gonzalez-Salazar, Yanin Chavarri-Guerra

Ecancermedicalscience 17 1633

PMID38414963
PMCIDPMC10898914
DOI10.3332/ecancer.2023.1633
发表日期2024-02-28
摘要

摘要

Breast cancer is the most common type of cancer globally. Hereditary breast cancer accounts for 10% of new cases and 4%-5% of cases are associated to pathogenic variants in BRCA1 or BRCA2 genes. In recent years, poly-adenosine-diphosphate-ribose polymerase inhibitors (PARPi) olaparib and talazoparib have been approved for patients with BRCA-associated, HER2 -negative breast cancer. These drugs have shown positive results in the early and advanced setting with a favourable toxicity profile based on the OlympiAD, OlympiA and EMBRACA phase 3 trials. However, patients included in these randomised trials are highly selected, making toxicity and efficacy in patients encountered in routine clinical care a concern. Since the approval of olaparib and talazoparib for advanced human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer, several phase IIIb-IV trials, expanded access cohorts, and retrospective cohorts have provided information on the efficacy and tolerability of these treatments in patient subgroups underrepresented in the registration trials, such as older adults, patients with poor performance status, and heavily pretreated patients. The aim of this review is to present a critical review of the information regarding the use of PARPi in real-world breast cancer patients.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。